<DOC>
	<DOCNO>NCT01663558</DOCNO>
	<brief_summary>Context : Men sex men ( MSM ) increase risk HPV-related anal neoplasia anal squamous cell carcinoma ; concomitant HIV infection roughly double risk . Objectives : 1 . To compare efficacy ablative therapy topical imiquimod therapy management anal dysplasia HIV-infected men . 2 . To describe relationship cytologic grade anal dysplasia ( report screen anal Pap test ) pathologic grade report anal mucosa histopathologic examination . 3 . To describe demographic , sexual practice , HPV-specific , HIV-specific correlate anal dysplasia . 4 . To describe adverse effect associate ablative therapy topical imiquimod therapy . Design : Prospective , randomize control clinical trial . This pilot study . All subject undergo baseline anal Pap , HRA biopsy indicate , anal HPV testing . If AIN 2 3 discover histopathologic examination , subject offer observation treatment . If chooses treatment , randomize : 1 ) imiquimod anal suppository three time weekly 3 month , 2 ) appropriate ablative therapy determine colorectal surgeon . During imiquimod treatment ( applicable ablative group treatment complete one visit ) subject follow 2 week , 4 week , 8 week , 12 week anal Pap , HRA biopsy indicate , anal HPV testing . After therapy complete treatment group , subject follow 1 month , 3 month , 6 month , 9 month , 12 month post-therapy anal Pap , HRA biopsy indicate , anal HPV testing . Observation subject evaluate every 3 month anal Pap , HRA biopsy indicate , anal HPV test 12 month . We choose goal 30 subject treatment group 10 subject observation group base likelihood enrol study type reasonable amount time . Main Outcome Measures : 1 . Anal Pap cytologic grade , include regression recurrence course study 2 . HPV type anal canal , include regression recurrence course study 3 . Anal histology , include regression recurrence course study 4 . Adverse effect experience treatment , record symptom log</brief_summary>
	<brief_title>Anal Dysplasia Study Men Who Have Sex With Men Living With HIV</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Papilloma</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Male gender , â‰¥18 year age HIVinfected take ARVs suppress HIV VL ( &lt; 48 copies/mL ) 2 consecutive measurement within previous 6 month Any CD4 count consider appropriate study Plasma INR &lt; 1.5 Plasma partial thromboplastin time ( PTT ) &lt; 35s Blood WBC &gt; 2.0x103/mm3 absolute neutrophil count &gt; 500 Blood hemoglobin &gt; 10.0 g/dL Blood platelet count &gt; 50x103/mm3 Serum total bilirubin &lt; 6.0 mg/dL ( subject take atazanavirbased ARV regimen may elevate total bilirubin generally &lt; 6 ) Blood aspartate aminotransferase ( AST ) &lt; 100 U/L ( &lt; 2 ULN ) Blood alanine aminotransferase ( ALT ) &lt; 130 U/L ( &lt; 2 ULN ) Serum creatinine &lt; 1.5 mg/dL ECOG performance status &lt; 3 Tricare beneficiary History AIN Anal canal condyloma require surgical treatment Anal cancer ( current history ) History prior anal surgery , include hyfrecation , excision , cryotherapy , photocoagulation Use anticoagulant ( warfarin , heparin , Pradaxa ) Inability attend study visit Participation drug study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>anal dysplasia</keyword>
	<keyword>HPV</keyword>
	<keyword>HIV</keyword>
	<keyword>MSM</keyword>
</DOC>